|Bid||1.2100 x 3100|
|Ask||1.2500 x 1300|
|Day's Range||1.2200 - 1.2600|
|52 Week Range||1.1600 - 12.9000|
|Beta (3Y Monthly)||2.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
NEW YORK, Sept. 04, 2019 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Oppenheimer.
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 4,475,000 shares of common stock at a price of $1.50 per share in a registered direct offering, resulting in total gross proceeds of approximately $6.7 million, before deducting the placement agents’ fees and other estimated offering expenses. The Company also agreed to issue to the investors unregistered warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement. The warrants have an exercise price of $1.78 per share of common stock, will be exercisable six months from the date of issuance and will expire four years following the date of issuance.
Every investor in Seelos Therapeutics, Inc. (NASDAQ:SEEL) should be aware of the most powerful shareholder groups...
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company, is pleased to announce the acceptance of the Investigation New Drug (IND) application for SLS-005 (trehalose) by the Food and Drug Administration (FDA). The FDA has advised Seelos that it may proceed with the proposed clinical trial SLS-005-201 for Mucopolysaccharidosis type III (Sanfilippo syndrome).
NEW YORK, Aug. 14, 2019 -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has granted a stock option to purchase.
NEW YORK, Aug. 06, 2019 -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that Raj Mehra, PhD, Chairman, Founder, and CEO.
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company, today released its second quarter pipeline update. “We have made tremendous progress on multiple programs,” emphasized Raj Mehra, Ph.D., Chairman and CEO of Seelos Therapeutics, “progressing with the initiation of a potentially pivotal study for SLS-005 in a broad spectrum of Sanfilippo syndrome A and B patients and including the C and D type patients in an expanded access program is a great achievement in an indication with paucity of therapeutic choices. “Additional preclinical studies are underway for SLS-007 to further characterize the peptides’ potential in targeting alpha-synuclein pathology in Parkinson’s Disease.
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase IIb/III clinical study of SLS-005 (trehalose) for the treatment of Sanfilippo syndrome (SFS). Seelos is working in collaboration and under a grant with Team Sanfilippo Foundation (TSF), a nonprofit foundation founded by parents of children with Sanfilippo syndrome. In May, Seelos announced the intention to expand this IND to be a combined Phase IIb/III, multicenter study designed to assess safety, tolerability and efficacy of trehalose IV in Sanfilippo A and B based on functional outcomes, biomarkers, neuro-cognitive assessments and quality of life measurements.
Team Sanfilippo Foundation to Provide Funding for Planned FDA/EMA Open-Label Phase IIb/III and Expanded Access Study in Sanfilippo Syndrome Initial Patient Dosing is.
NEW YORK, July 02, 2019 -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they have received a Notice of Allowance.
NEW YORK, July 01, 2019 -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has been added to the Russell Microcap®.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Cemtrex, Inc. (NASDAQ: CETX ) shares were ...
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company, announced today the exclusive worldwide licensing of a gene therapy program targeting the regulation of the SNCA gene, which encodes alpha-synuclein expression, from Duke University. In addition, accumulating evidence suggests that elevated levels of wild-type alpha-synuclein are causative in the pathogenesis of PD. The role of SNCA overexpression in PD pathogenesis and the need to maintain normal physiological levels of alpha-synuclein protein emphasize the so-far unmet need to develop new therapeutic strategies, such as SLS-004, targeting the regulatory mechanisms of SNCA expression.
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company provided an update on recent pipeline developments and corporate highlights. “Seelos will be meeting with FDA to design and initiate a Proof-of-Concept (PoC) study in patients with post-traumatic stress disorder (PTSD) at imminent risk of suicide,” said Raj Mehra, PhD, Chairman, Founder, and CEO of Seelos.
“We have made tremendous progress in our acquired programs as we are finalizing the phase 2b/3 design for Sanfilippo under a Seelos IND for SLS-005 and have initiated the in-vivo studies for SLS-007,” said Raj Mehra, Ph.D., CEO of Seelos Therapeutics. On January 24th, Seelos Therapeutics completed its merger with Apricus and began trading under the symbol “SEEL” on the NASDAQ.
NEW YORK, April 16, 2019 -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they will present and host 1x1 and small.
NEW YORK, NY / ACCESSWIRE / April 2, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
Thinly traded nanocap biotech Seelos Therapeutics Inc (NASDAQ: SEEL) is trading sharply higher on over three times its average volume. Seelos, which develops therapies for central nervous system disorders and other rare conditions, issued an update after the close Thursday on its pipeline development as well as corporate highlights. Since the completion of the reverse merger Jan. 24, Seelos has acquired two candidates: SLS-005 targeting orphan diseases of the CNS; and SLS-007 targeting alpha-synuclein aggregates in Parkinson's disease.
CORAL GABLES, FL / ACCESSWIRE / March 27, 2019 / The future of the healthcare stock market is directly correlated to whether companies in the healthcare sector have what it takes to meet the growing health challenges facing society. According to recent statistics, global shortages in primary care physicians coupled with rising populations has left millions without access to acute care. Luckily, there are healthcare companies rising to the challenge with innovative medical technologies and nuanced approaches to how we treat and care for our patients.
The FDA recently took a big step towards blessing the emerging field of brain-computer interfacing technology, which has broad application in prosthetics and even enhancing the human brain. Visionaries like Elon Musk are betting on the latter happening quickly, and startups like his are designing software and hardware to capitalize on new technology breakthroughs. This field of neurology, sometimes known as neuromodulation, has only recently come into the pubic markets spotlight with companies like electroCore, Inc. (ECOR) and Nuvectra (NVTR) going public with technology that can assuage pain through electric stimulation of the nervous system.
CORAL GABLES, FL / ACCESSWIRE / March 8, 2019 / The healthcare stock market has seen impressive gains in the first few months of 2019 as we've seen several major shifts to the healthcare system in the U.S. In the last few years, by virtue of technological advancements and cultural changes, the healthcare industry has become increasingly more patient-centered. Until recently, patients were less vocal about their needs and the privacy of their medical records, but, just like consumers advocating for better customer experience, so, too, are patients expecting quality from their care providers. If companies in the healthcare sector continue to rise to the growing challenges presented by new diseases, patient expectations, and the ever-changing political climate, investors looking for potential opportunities could benefit from keeping healthcare on their radar.
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company, announced today that it has acquired an exclusive license to intellectual property owned by The Regents of the University of California (The UC Regents) pertaining to a technology that was created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein). Seelos plans to study this initial approach in Parkinson's disease (PD) and will further evaluate the potential clinical approach in other disorders affecting the central nervous system (CNS).
CORAL GABLES, FL / ACCESSWIRE / March 6, 2019 / The tech stock market has been a hotbed of exciting conversation during the last few months as a result of word spreading about tech companies taking innovative approaches to create new technologies for the betterment of humankind. Stemming from the belief that consumers deserve to live life to the best of their ability, these tech companies have pioneered technological advancements in the areas of augmented reality, cloud computing, and countless others. ParcelPal Technology Inc (PTNYF) (PKG), Seelos Therapeutics Inc (SEEL), Renren Inc (RENN), and Ohr Pharmaceutical Inc (OHRP) represent 4 tech stocks on the rise on Wednesday.